Diabetes Care, Vol 22, Issue 8 1296-1301, Copyright © 1999 by American Diabetes Association

ARTICLES

Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy

D Ziegler, M Hanefeld, KJ Ruhnau, H Hasche, M Lobisch, K Schutte, G Kerum and R Malessa
Diabetes-Forschungsinstitut an der Heinrich-Heine-Universitat, Dusseldorf, Germany. dan.ziegler@dfi.uni-duesseldorf.de

OBJECTIVE: To evaluate the efficacy and safety of alpha-lipoic acid given intravenously, followed by oral treatment in type 2 diabetic patients with symptomatic polyneuropathy. RESEARCH DESIGN AND METHODS: In a multicenter randomized double-blind placebo-controlled trial (Alpha-Lipoic Acid in Diabetic Neuropathy [ALADIN] III Study), 509 outpatients were randomly assigned to sequential treatment with 600 mg alpha-lipoic acid once daily intravenously for 3 weeks, followed by 600 mg alpha-lipoic acid three times a day orally for 6 months (A-A; n = 167); 600 mg alpha-lipoic acid once daily intravenously for 3 weeks, followed by placebo three times a day orally for 6 months (A-P; n = 174); and placebo once daily intravenously for 3 weeks, followed by placebo three times a day orally for 6 months (P-P; n = 168). Outcome measures included the Total Symptom Score (TSS) for neuropathic symptoms (pain, burning, paresthesias, and numbness) in the feet, and the Neuropathy Impairment Score (NIS). Data analysis was based on the intention to treat. RESULTS: No significant differences between the groups were noted for the demographic variables and the nerve function parameters at baseline. The TSS in the feet decreased from baseline to day 19 (median [range]) by -3.7 (-12.6 to 5.0) points in the group given alpha-lipoic acid intravenously and by -3.0 (-12.3 to 8.0) points in the placebo group (P = 0.447), but the area under curve on a daily basis was significantly smaller in the active as compared with the placebo group (85.6 [0-219] vs. 95.9 [5.5-220]); P = 0.033). After 7 months, the changes in the TSS from baseline were not significantly different between the three groups studied, which could be due to increasing intercenter variability in the TSS during the trial. The NIS decreased after 19 days by -4.34+/-0.35 points (mean +/- SEM) in A-A and A-P and -3.49+/-0.58 points in P-P (P = 0.02 for alpha-lipoic acid versus placebo) and after 7 months by -5.82+/-0.73 points in A-A, -5.76+/-0.69 points in A-P, and -4.37+/-0.83 points in P-P (P = 0.09 for A-A vs. P-P). The rates of adverse events were not different between the groups throughout the study. CONCLUSIONS: These findings indicate that a 3-week intravenous treatment with alpha-lipoic acid, followed by a 6-month oral treatment, had no effect on neuropathic symptoms distinguishable from placebo to a clinically meaningful degree, possibly due to increasing intercenter variability in symptom scoring during the study. However, this treatment was associated with a favorable effect on neuropathic deficits without causing significant adverse reactions. Long-term trials that focus on neuropathic deficits rather than symptoms as the primary criterion of efficacy are needed to see whether oral treatment with alpha-lipoic acid over several years may slow or reverse the progression of diabetic neuropathy.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. A Little, J. L Edwards, and E. L Feldman Diabetic neuropathies Practical Neurology, April 1, 2007; 7(2): 82 - 92. [Full Text] [PDF]

				T. S. Foster Efficacy and Safety of {alpha}-Lipoic Acid Supplementation in the Treatment of Symptomatic Diabetic Neuropathy The Diabetes Educator, January 1, 2007; 33(1): 111 - 117. [Abstract] [Full Text] [PDF]

				A. A.F SIMA and H. KAMIYA Diabetic Neuropathy Differs in Type 1 and Type 2 Diabetes Ann. N.Y. Acad. Sci., November 1, 2006; 1084(1): 235 - 249. [Abstract] [Full Text] [PDF]

				A. G. Huebschmann, J. G. Regensteiner, H. Vlassara, and J. E.B. Reusch Diabetes and Advanced Glycoxidation End Products. Diabetes Care, June 1, 2006; 29(6): 1420 - 1432. [Full Text] [PDF]

				V Bansal, J Kalita, and U K Misra Diabetic neuropathy Postgrad. Med. J., February 1, 2006; 82(964): 95 - 100. [Abstract] [Full Text] [PDF]

				V Yadav, G Marracci, J Lovera, W Woodward, K Bogardus, W Marquardt, L Shinto, C Morris, and D Bourdette Lipoic acid in multiple sclerosis: a pilot study Multiple Sclerosis, April 1, 2005; 11(2): 159 - 165. [Abstract] [PDF]

				A. A.F. Sima, M. Calvani, M. Mehra, A. Amato, and for the Acetyl-l-Carnitine Study Group Acetyl-L-Carnitine Improves Pain, Nerve Regeneration, and Vibratory Perception in Patients With Chronic Diabetic Neuropathy: An analysis of two randomized placebo-controlled trials Diabetes Care, January 1, 2005; 28(1): 89 - 94. [Abstract] [Full Text] [PDF]

				R. J Cersosimo Oxaliplatin-Associated Neuropathy: A Review Ann. Pharmacother., January 1, 2005; 39(1): 128 - 135. [Abstract] [Full Text] [PDF]

				A. M. Vincent, J. W. Russell, P. Low, and E. L. Feldman Oxidative Stress in the Pathogenesis of Diabetic Neuropathy Endocr. Rev., August 1, 2004; 25(4): 612 - 628. [Abstract] [Full Text] [PDF]

				A. J.M. Boulton, R. A. Malik, J. C. Arezzo, and J. M. Sosenko Diabetic Somatic Neuropathies Diabetes Care, June 1, 2004; 27(6): 1458 - 1486. [Full Text] [PDF]

				J. Teichert, R. Hermann, P. Ruus, and R. Preiss Plasma Kinetics, Metabolism, and Urinary Excretion of Alpha-Lipoic Acid following Oral Administration in Healthy Volunteers J. Clin. Pharmacol., November 1, 2003; 43(11): 1257 - 1267. [Abstract] [Full Text] [PDF]

				E. Rock and A. DeMichele Nutritional Approaches to Late Toxicities of Adjuvant Chemotherapy in Breast Cancer Survivors J. Nutr., November 1, 2003; 133(11): 3785S - 3793. [Abstract] [Full Text] [PDF]

				A. Scala, L. Checchi, M. Montevecchi, I. Marini, and M.A. Giamberardino UPDATE ON BURNING MOUTH SYNDROME: OVERVIEW AND PATIENT MANAGEMENT Crit. Rev. Oral. Biol. Med., July 1, 2003; 14(4): 275 - 291. [Abstract] [Full Text] [PDF]

				A. S. Ametov, A. Barinov, P. J. Dyck, R. Hermann, N. Kozlova, W. J. Litchy, P. A. Low, D. Nehrdich, M. Novosadova, P. C. O'Brien, et al. The Sensory Symptoms of Diabetic Polyneuropathy Are Improved With {alpha}-Lipoic Acid: The SYDNEY Trial Diabetes Care, March 1, 2003; 26(3): 770 - 776. [Abstract] [Full Text] [PDF]

				C. Gedlicka, G. V. Kornek, K. Schmid, and W. Scheithauer Amelioration of docetaxel/cisplatin induced polyneuropathy by {alpha}-lipoic acid Ann. Onc., February 1, 2003; 14(2): 339 - 340. [Full Text] [PDF]

				K. M. Halat and C. E. Dennehy Botanicals and Dietary Supplements in Diabetic Peripheral Neuropathy J Am Board Fam Med, January 1, 2003; 16(1): 47 - 57. [Abstract] [Full Text] [PDF]

				C. Gedlicka, W. Scheithauer, B. Schull, and G.V. Kornek Effective Treatment of Oxaliplatin-Induced Cumulative Polyneuropathy With Alpha-Lipoic Acid J. Clin. Oncol., August 1, 2002; 20(15): 3359 - 3361. [Full Text] [PDF]

				M. F. Melhem, P. A. Craven, J. Liachenko, and F. R. DeRubertis {alpha}-Lipoic Acid Attenuates Hyperglycemia and Prevents Glomerular Mesangial Matrix Expansion in Diabetes J. Am. Soc. Nephrol., January 1, 2002; 13(1): 108 - 116. [Abstract] [Full Text] [PDF]

				L. Shane-McWhorter Biological Complementary Therapies: A Focus on Botanical Products in Diabetes Diabetes Spectr, October 1, 2001; 14(4): 199 - 208. [Abstract] [Full Text] [PDF]

				R. C. Ruhe and R. B. McDonald Use of Antioxidant Nutrients in the Prevention and Treatment of Type 2 Diabetes J. Am. Coll. Nutr., October 1, 2001; 20(90005): 363S - 369. [Abstract] [Full Text]

				D. Konrad, R. Somwar, G. Sweeney, K. Yaworsky, M. Hayashi, T. Ramlal, and A. Klip The Antihyperglycemic Drug {alpha}-Lipoic Acid Stimulates Glucose Uptake via Both GLUT4 Translocation and GLUT4 Activation: Potential Role of p38 Mitogen-Activated Protein Kinase in GLUT4 Activation Diabetes, June 1, 2001; 50(6): 1464 - 1471. [Abstract] [Full Text]

				D. Luft Neuropathic pain in diabetic nephropathy—update on analgesic strategies Nephrol. Dial. Transplant., October 1, 1999; 14(10): 2285 - 2288. [Full Text] [PDF]